Case Reports
7 July 2022
Vol. 15 No. 1 (2023)
https://doi.org/10.4081/dr.2022.9534

Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Carcinoma, Basal Cell, Chemoprevention, Lenalidomide, Skin Neoplasm
907
Views
346
Downloads
35
HTML

Authors

Calogero Pagliarello
calogero.pagliarello@libero.it
https://orcid.org/0000-0001-7169-4829
UO Multizonale Dermatologia Ospedale Santa Chiara, Trento, Italy.
Carlo Renè Girardelli
UO Multizonale Dermatologia Ospedale Santa Chiara, Trento, Italy.
Ignazio Stanganelli
Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma; Skin Cancer Unit IRCCS IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol 2016;7:209-21.
Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol 2004;51:293-300.
Nahmias Z, Nambudiri VE, Vleugels RA. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. J Am Acad Dermatol 2016;75:210-2.
Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-7.
FactMed Medication Safety Directory. Available from: http://factmed.com/study-lenalidomide-causing-BASAL%20CELL%20CARCINOMA.php Accessed on: 19 February 2017.
Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015;373:1618-26.

How to Cite



Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists. (2022). Dermatology Reports, 15(1). https://doi.org/10.4081/dr.2022.9534
Copyright (c) 2022 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.